Standout Papers

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, control... 2017 2026 2020 2023 385
  1. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial (2017)
    Ari Green, Jeffrey M. Gelfand et al. The Lancet

Immediate Impact

2 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

GPCR drug discovery: new agents, targets and indications
2025 Standout
Macrophage polarization: an important role in inflammatory diseases
2024 Standout
1 intermediate paper

Works of Justin Inman being referenced

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
Justin Inman 54 18 201 170 131 5 445
N. Amberger 67 23 93 77 69 8 416
Monika Albert 13 6 275 152 141 7 494
Yuji Mikami 25 64 176 98 82 13 415
Daniel Holl 65 59 147 91 116 10 487
Samuel K. Jensen 9 12 159 191 186 10 496
Melissa A. Maddie 48 80 197 34 53 10 492
Irène Coman 33 11 87 121 72 9 401
Alexandra Yvon 20 24 132 122 31 10 446
Dalton W. Dietrich 14 33 131 83 90 5 394
Gaetano Desina 26 78 106 59 48 10 495

All Works

Loading papers...

Rankless by CCL
2026